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To the Editor -In the Second Regulatory Review on Nanomaterials 1 , the European Commission acknowledges that nanomaterials are revolutionary materials and that important challenges exist in regard to hazard and exposure assessments. Yet, they conclude that current risk-assessment methods are applicable to nanomaterials, and that the European chemical legislative (known as REACH: Registration, Evaluation, Authorisation and Restriction of Chemicals) "…sets the best possible framework for the risk management of nanomaterials" 1 .
Here, I argue that significant changes to REACH and the accompanying annexes are required to answer the call made by the public, downstream users and progressive businesses for clearer and more definite regulatory rules specific to nanomaterials 2 . Under REACH, unambiguous substance identification is essential 3 . Briefly, a chemical substance is defined by its chemical composition including any additive used to preserve stability and any impurity derived from the processes used for its manufacture 4 . Substance identity is therefore independent of, for instance, primary particle size distribution and various surface treatments, which are necessary to stabilize the substance. This means nanomaterials with markedly different properties -for example, the bulk and nanoform of a material, or various forms of surface-treated nanomaterials 5, 6 -are considered to be the same under REACH. In the European Commission's Staff Working Paper 7 , which accompanies the Second Regulatory Review on Nanomaterials 1 , over 60 nanomaterials are cited to be on the market. Yet, a survey by the European Commission and the European Chemicals Agency (ECHA) found only seven nanomaterials were registered under REACH in the first round of registrations in 2010 as -among others -substances that were produced and imported at >1,000 tons per year 7, 8 . For correct and unambiguous substance identification, a distinction between the bulk and the nanoforms of a given material needs to be specified in the legal text of REACH 9 . Furthermore, the European Commission should acknowledge that nanomaterials cannot be identified solely by chemical composition, and that additional main identifiers (such as primary particle size distribution, shape (including aspect ratio), specific surface area and surface treatment) should be included in the Technical Guidance for Identification and Naming of Substances provided by ECHA 3 . Only this will make clear that the properties and behaviour of nanomaterials differ fundamentally from each other and from the bulk 5 . Specific substance identification of nanomaterials could mean that some would not meet REACH's tonnage bands, which lay down the environmental, health and safety information requirements that need to be met by industry. Although lowering the tonnage band to, for example, 1 kg (ref. 10) has been suggested, I contend that if nanomaterials are commercialized in Europe, their registration should be independent of production volumes, and submission of (eco)toxicological data to regulators should be mandatory. Moreover, given the urgency of generating data on nanomaterials, registration fees must be reduced to encourage registration. As recommended by the consortium contracted by the European Commission to advise on fulfilling information requirements for nanomaterials under REACH, manufacturers should be required to perform accurate physicochemical characterization using multiple techniques because this is essential for assessing the potential (eco)toxicity of nanomaterials 11 . Furthermore, ECHA should offer confidential technical assistance to small-and medium-sized enterprises to meet these requirements and to ensure the innovation of safe nanomaterials 12 . . Moreover, monitoring and detection equipment for exposure assessment need to be developed and there are no standards on how to measure nanoparticle dose in humans, the workplace and the environment 14 . Even if required only for commercialized nanomaterials, caseby-case risk assessment of nanomaterials is time-and resource-intensive 15 as outlined in the 2012 report by SCENIHR and two other scientific committees 16 . Under the heading '5.2.Towards a new conceptual framework in risk assessment' , the report states "It is also evident that the risks posed by a number of products from new technologies (for example, biological products, manufactured nanomaterials) are unlikely to be adequately assessed using current methodologies alone" 16 . Another disturbing aspect of the Second Regulatory Review on Nanomaterials 1 is that it focuses only on first-generation nanomaterials (that is, passive nanostructures such as nanoparticles). The Staff Working Paper 7 acknowledges that second-and third-generation nanomaterials (for example, targeted drug-delivery systems and novel robotic devices) are entering early stages of market development, yet they offer no vision or strategic planning in ensuring the generation and development of The European Union's chemical legislation needs revision correspondence environmental, health and safety information, and regulations in a timely manner.
In contrast to the
Finally, the European Commission repeatedly downplay the concerns by stating that 1 "…nanomaterials are similar to normal chemicals/substances in that some may be toxic and some may not. " The analogy highlights that manufacturers, scientists and the European Commission are not aware of which nanomaterials are toxic just as we did not know about industrial chemicals before they came into widespread use during the twentieth century, resulting in significant human health and environmental damage as documented by the European Environmental Agency 17, 18 . One fears that the European Commission either does not understand the challenges and problems before them when it comes to regulation and risk assessment of nanomaterials, or they grossly underestimate them.
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